Authors

Amy Jones, MD

Latest:

Dr. Jones on Future Research Efforts in Pancreatic Cancer

Amy Jones, MD, discusses future research efforts in pancreatic cancer.

Nosha Farhadfar, MD

Latest:

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Giovanni Marconi, MD

Latest:

Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDS

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.

Sam Klempner, MD

Latest:

Dr Klempner on the FDA Approval of Zolbetuximab for CLDN18.2+, HER2– Gastric or GEJ Adenocarcinoma

Samuel J. Klempner, MD, discusses the FDA approval of zolbetuximab for CLDN18.2+, HER2–, locally advanced unresectable or metastatic gastric/GEJ adenocarcinoma.

Brian Henick, MD

Latest:

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Benjamin Herzberg, MD

Latest:

Moving From Passive to Active Clinical Trials Enrollment

The Herbert Irving Comprehensive Cancer Center has developed processes to actively screen any patient with a relevant mutation for an open trial.

Nausheen Ahmed, MD

Latest:

Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCL

Nausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.

Sarah Rutherford, MD, Weill Cornell Medical College

Latest:

Hematologic Malignancies Talk: Exciting Updates from ASH 2020 Virtual Meeting

Eric K. Singhi, MD

Latest:

Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer

Eric Kumar Singhi, MD, discusses the identification of current care gaps and unmet needs in small cell lung cancer.

Kedar Kirtane, MD

Latest:

Dr Kirtane on the Design of a Phase 1b Trial of Tbio4101 Plus Pembrolizumab in HNSCC

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

USC Norris Comprehensive Cancer Center

Latest:

USC Study Explores New Insights into Innate Eesistance for Immunotherapies in Colorectal Cancer

Researchers find evidence that simultaneously targeting the innate and adaptive immune systems holds promise for treating aggressive colon cancer cases.

Shonali Midha, MD

Latest:

Dr Midha on Real-World Data With Teclistamab in Relapsed/Refractory Multiple Myeloma

Shonali Midha, MD, discusses real-world data with teclistamab in patients with relapsed/refractory multiple myeloma.

Christina Brennan, MD, MBA, FACRP

Christina Brennan, MD, MBA, FACRP, is senior vice president of clinical research at The Feinstein Institutes for Medical Research at Northwell Health.

Latest:

A Close Look at Clinical Trials in Oncology and Beyond: Looking Toward the Future

In this last episode, experts underscore the importance of incorporating the patient voice into clinical trial processes.

Faiz Anwer, MD

Latest:

Dr. Anwer on the Efficacy of CAR T-Cell Therapy in Multiple Myeloma

Faiz Anwer, MD, discusses the efficacy of CAR T-cell therapy in multiple myeloma.

Pannaga G. Malalur, MBBS

Latest:

Dr Malalur on Addressing Unmet Needs in Pancreatic Cancer

Pannaga G. Malalur, MBBS, discusses several unmet needs within pancreatic cancer, including the implementation of updated germline genetic testing guidelines, increased screening of high-risk patients, and improved sequencing of available therapeutics.

Manjusha Namuduri, MD

Latest:

CAR T Pioneers Describe Challenges Faced in Cancer

Advances of chimeric antigen receptor T-cell therapy technologies are in rapid development and under investigation in a range of preclinical and clinical research around the globe.

Rohit Kumar, MD

Latest:

Dr. Kumar on Immunotherapy Combinations in RCC

Rohit Kumar, MD, discusses the benefits of combining immunotherapy agents with each other or with TKIs in patients with renal cell carcinoma and the unmet needs that remain for patients with RCC who do not respond to immunotherapy.

DONALD J. JOHANN JR, MD, MSC

Latest:

UAMS Winthrop P. Rockefeller Cancer Institute Pushes Liquid Biopsy Research Forward

The use of a routine blood test to assess and monitor patients with cancer, especially in a longitudinal manner, has long been the holy grail of cancer research.

Monica A. Patel, MD

Latest:

Dr. Patel on Selecting Patients for Treatment With Atezolizumab/Bevacizumab in HCC

Monica A. Patel, MD, discusses factors that determine whether a patient with hepatocellular carcinoma is a good candidate to receive a combination of atezolizumab and bevacizumab.

Jack Khouri, MD

Latest:

Unprecedented Advances Fuel Progress in the Treatment of AL Amyloidosis

Light-chain amyloidosis is a rare plasma cell disorder that involves the production of a misfolded amyloidogenic light chain by a plasma cell clone that deposits in various organs leading to organ failure.